# Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

> **NCT05199571** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 99 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Ofatumumab

## Key facts

- **NCT ID:** NCT05199571
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-22
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05199571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05199571, "Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05199571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*